Aspira Women's Health Inc.

Price Chart

Risk-Adjusted Performance

Aspira Women's Health Inc. (AWHL) Price Performance

Aspira Women's Health Inc. (AWHL) trades on United States in USD. The company is classified in the Healthcare sector under the In Vitro & In Vivo Diagnostic Substances industry. The stock currently trades at $0.29, down 7.74% from the previous close.

Over the past year, AWHL has traded between a low of $0.02 and a high of $0.69. The stock has gained 179.6% over this period. It is currently 57.6% below its 52-week high.

Aspira Women's Health Inc. has a market capitalization of $13.20M.

About Aspira Women's Health Inc.

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force; Aspira Synergy platform; and with marketing and distribution agreements. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs, and proteins; and a strategic alliance agreement with Quest Diagnostics Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.